September 12, 2017
Results from the phase 3 Liberty Asthma Quest trial demonstrated that the investigational drug, dupilumab, reduced severe exacerbations and improved lung function in patients with uncontrolled persistent asthma, according to a press release issued by Regeneron Pharmaceuticals and Sanofi.
“Approximately one million U.S. adults and adolescents live with uncontrolled, persistent asthma, and continue to experience serious asthma attacks, despite taking an intensive regimen of standard therapies,” George D. Yancopoulos, MD, PhD, president and chief scientific officer of Regeneron, said in the release. “Dupilumab has now demonstrated positive late-stage results in two serious allergic diseases — asthma and atopic dermatitis — with robust efficacy and an extensive safety database. These results continue to support our hypothesis that the [interleukin (IL)]-4/IL-13 pathway is a critical driver of allergic disease, and we remain committed to further investigating the IL-4/IL-13 pathway in other allergic diseases.”